In silico prediction of skin metabolism and its implication in toxicity assessment by Madden, JC et al.
Accepted Manuscript
In Silico Prediction of Skin Metabolism and its Implication in Toxicity Assess-
ment
J.C. Madden, S. Webb, S.J. Enoch, H.E. Colley, C. Murdoch, R. Shipley, P.
Sharma, C. Yang, M.T.D. Cronin
PII: S2468-1113(17)30032-4
DOI: http://dx.doi.org/10.1016/j.comtox.2017.07.001
Reference: COMTOX 20
To appear in: Computational Toxicology
Received Date: 5 May 2017
Revised Date: 12 June 2017
Accepted Date: 3 July 2017
Please cite this article as: J.C. Madden, S. Webb, S.J. Enoch, H.E. Colley, C. Murdoch, R. Shipley, P. Sharma, C.
Yang, M.T.D. Cronin, In Silico Prediction of Skin Metabolism and its Implication in Toxicity Assessment,
Computational Toxicology (2017), doi: http://dx.doi.org/10.1016/j.comtox.2017.07.001
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and
review of the resulting proof before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
  
1 
 
In Silico Prediction of Skin Metabolism and its Implication in Toxicity Assessment  
 
JC Madden
a
, S Webb
b
, SJ Enoch
a
, HE Colley
c
, C Murdoch
c
, R Shipley
d
, P Sharma
e
, C Yang
f
, and MTD Cronin
a
 
a
School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool, 
L3 3AF, UK; 
b
Department of Applied Mathematics, Liverpool John Moores University, Byrom Street, 
Liverpool L3 3AF, UK; 
c
School of Clinical Dentistry, University of Sheffield, Claremont Crescent, Sheffield, 
S10 2TA, UK, dDepartment of Mechanical Engineering, University College London, Gower Street, London, 
WC1E 6BT, UK; 
e
Department of Molecular and Clinical Pharmacology, MRC Centre for Drug Safety Science, 
Institute of Translational Medicine, University of Liverpool, Sherrington Building, Liverpool, L69 3GE, UK; 
fMolecular Networks GmbH - Computerchemie, Henkestrasse 91, 91052 Erlangen, Germany 
Corresponding author: Judith Madden 
E-mail: j.madden@ljmu.ac.uk 
Tel: +44 (0)151 231 2032 
 
Abstract 
Skin, being the largest organ of the body, represents an important route of exposure, not only for the 
abundance of chemicals present in the environment, but also for products designed for topical application 
such as drugs and personal care products. Determining whether such incidental or intentional exposure 
poses a risk to human health requires consideration of temporal concentration, both externally and 
internally, in addition to assessing the chemical’s intrinsic hazard. In order to elicit a toxic response in vivo 
the chemical must reach its site of action in sufficient concentration, as determined by its absorption, 
distribution, metabolism and elimination (ADME) profile. Whilst absorption and distribution into and 
through skin layers have been studied for decades, only more recently has skin metabolism become a 
subject of intense research, now recognised as playing a key role in both toxification and detoxification 
processes. The majority of information on metabolic processes, however, has generally been acquired via 
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studies performed on the liver. This paper outlines strategies that may be used to leverage current 
knowledge, gained from liver metabolism studies, to inform predictions for skin metabolism through 
understanding the differences in the enzymatic landscapes between skin and liver. The strategies outlined 
demonstrate how an array of in silico tools may be used in concert to resolve a significant challenge in 
predicting toxicity following dermal exposure. The use of in vitro methods for determining skin metabolism, 
both to provide further experimental data for modelling and to verify predictions is also discussed. Herein, 
information on skin metabolism is placed within the context of toxicity prediction for risk assessment, 
which requires consideration of both exposure and hazard of parent chemicals and their metabolites. 
Keywords 
In silico, in vitro, skin metabolism, toxicity prediction 
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Introduction 
Human skin is continually exposed to an abundance of diverse chemicals present in the environment, home, 
workplace or in products directly applied to the skin surface. Chemicals responsible for incidental exposure 
include industrial chemicals, pollutants, household or industrial cleaning and fragrancing products. 
Intentional exposure via skin occurs as a result of the application of personal care products, cosmetics or 
topical drug formulations. The ability of a chemical to elicit toxicity in humans, or indeed in any organism, is 
governed by three factors: (i) the intrinsic hazard of the chemical (or transformation product thereof); (ii) 
the potential for external exposure i.e. the presence of the chemical in the environment or in a topically 
applied product; and (iii) the ability of the chemical (or its transformation products) to reach its site of 
action in the body at adequate concentration. Knowledge of these three factors is essential in performing 
risk assessment, however, to obtain such information for all chemicals of interest via empirical testing 
would not be economically or practicably feasible nor would it be ethically responsible in terms of animal 
use. The application of alternative methods in evaluation of chemicals, or in risk assessment, is therefore 
essential. Whilst predictive toxicology has been used to address these issues for many years, metabolism 
has often proved to be a confounding factor that requires specific or inherent incorporation into the 
modelling process. Complications can arise in model building where it is the transformation product, rather 
than the parent molecule, that is responsible for the activity. Problems arising from metabolic activation 
and the presence of reactive metabolites, particularly following oral drug administration, are now well 
recognised and this has led to greater interest in predicting the identity of metabolites and their rate and 
extent of formation. Although it is known that the majority of organs possess metabolic capability, 
metabolism studies have predominantly focused on the liver - the main organ of metabolism and of key 
importance following oral exposure. As the skin is one of the most important routes of exposure, it is now 
recognised that predicting metabolism in skin is essential to obtaining accurate predictions of potential 
toxicity or activity (e.g. in the case of topical drug administration). There are several differences to consider 
between oral and dermal routes and incidental versus intentional exposure to chemicals. These factors 
include: frequency and duration of application or ingestion; concentration of the chemical; enzyme 
expression at the site of exposure or site of distribution; and the ease of uptake or distribution from the 
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site. Notably, skin has evolved to provide a barrier function whereas the gastro-intestinal tract is designed 
for the uptake of essential nutrients. Also, toxicity testing has traditionally involved (relatively) high 
concentration, acute, oral dosing, whereas use of personal care products is generally a low dose, long term 
application. A wealth of information now exists relating to oral absorption and liver metabolism, this 
includes information on uptake, rate and extent of metabolite formation, metabolite identity, enzymes 
responsible and their expression. It is now possible to leverage this important data and apply it to 
predictions of skin uptake and metabolism, providing appropriate adjustments are made. Such adjustments 
need to take account of differences in exposure scenarios, uptake potential and enzyme expression / 
activity levels. This paper identifies various sources of information and in silico tools that may be applied to 
predicting skin metabolism and potential toxicity following dermal exposure. How the knowledge acquired 
from the application of these in silico tools can be put together in an overall predictive strategy is discussed, 
as well as the importance of incorporating further data from in vitro studies for modelling and verification 
purposes.  
 
Skin metabolism in the context of toxicity prediction 
Many factors determine the likelihood of a chemical eliciting local or systemic toxicity following dermal 
exposure. The significance of skin metabolism has increasingly been recognised and whilst this forms the 
focus of this paper, other aspects must also be considered in order to place the role of metabolism in 
context. Figure 1 shows the numerous elements governing the potential to elicit toxicity and where skin 
metabolism fits within this overall scheme. 
Figure 1 HERE 
As illustrated in Figure 1, a wide range of data types are required in order to reach an informed decision. 
Fortunately, there are many in silico tools, and other data sources, that may be leveraged to fill the gaps in 
knowledge relating to uptake, metabolism and potential toxicity of chemicals following dermal exposure. 
Leveraging such information can also lead to the development of more robust models, particularly where 
experimental data can be used to develop improved models and verify predictions in an iterative process.  
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Historically, data have predominantly been accumulated following oral administration to test subjects or 
obtained from in vitro liver assays. This has led to a wealth of information being generated, albeit for an 
alternative exposure scenario. Table 1 lists the potential data sources that could be used to fill gaps in 
knowledge relating to skin metabolism, provided that appropriate adjustments are made to account for the 
differences between the oral and dermal routes. 
Table 1 HERE 
As alluded to above, it is not only skin metabolism per se that determines the potential for toxicity, it is also 
influenced by a plethora of additional, inter-related factors that require consideration. Table 2 (and 
references provided therein) provides useful sources of data for these additional factors, relevant to overall 
risk assessment.  
Table 2 HERE 
Tables 1 and 2 indicate the diverse resources available that can be utilised to make predictions for 
individual components within the process of assessing toxicity. The individual elements can then be 
rationally combined within an encompassing predictive model. In this manner, deconstructing the problem 
into individual components, allows greater use of different data types and more flexible adjustment of the 
individual factors that are relevant to the overall prediction. Each of the individual components, sources of 
information and adjustments necessary for the development of predictive models, as given in Tables 1 and 
2, are discussed individually below. 
 
1. The role of skin metabolism  
Skin metabolism is an area that has attracted much recent interest due to its role in toxification or 
detoxification processes following dermal exposure. Improvements in analytical techniques have led to 
many metabolising enzymes being detected in skin. Although enzyme expression and activity levels are 
generally much lower than liver, cumulatively, given the large area of the skin, the net capacity for 
metabolism may be significant. It is recognised that many skin sensitisers require metabolic activation to 
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elicit their toxicity, conversely, minoxidil (a therapeutic agent used in treatment of hair loss) requires 
metabolic activation in skin in order to be effective [10]. Thus skin metabolism may be involved in 
toxification, detoxification or pro-drug activation processes. Identification and, where possible, quantitative 
estimation of metabolic capacity, is essential to determining the potential for chemicals to be activated or 
deactivated in the skin - a key factor in toxicity prediction and prioritisation of chemicals for further testing. 
Factors relevant to skin metabolism may be subdivided into distinct categories, each of these is 
summarised and discussed in more detail below (see sections 1.1 – 1.7). In silico tools that are available to 
assist in the prediction of these individual factors, associated with skin metabolism, are presented in Table 
3. Note that many of these tools have been based on liver metabolism studies, however, knowledge 
obtained from these can be usefully applied to the issue of skin metabolism provided appropriate 
adjustments are made. The information provided in Table 3 (and references therein) is indicative of the 
types of resources available and is not an exhaustive list. Tables 3 and 5, both pertaining to relevant 
software for metabolism prediction, incorporate information from the excellent overview provided by 
Kirchmair [12]. The “Click2Drug” website of the Swiss Institute of Bioinformatics 
(https://www.click2drug.org/index.html; accessed May 2017) is also noteworthy as it provides an updated 
and comprehensive listing, with brief description, of software, databases and webservices useful in drug 
design including a range of tools for ADME and toxicity prediction. 
Table 3 HERE 
 
1.1 Identification of the biotransformation pathway and enzyme(s) responsible 
An initial step in predicting metabolism of a given chemical is identifying the relevant reaction pathway and 
which enzyme(s) may be involved in catalysing the process. Knowledge of the metabolic reactions of the 
parent chemical, or similar chemicals, may be available from the literature. For example, comprehensive 
reviews of biotransformation and bioactivation pathways have been published [13, 14]. As manual 
investigation of such literature sources may be time consuming in silico tools based on such acquired 
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knowledge are useful in providing more rapid predictions of potential interactions between a given 
substrate and a putative enzyme. Models have also been derived to classify which substrates are more 
likely to be metabolised by a particular cytochrome P450 (CYP) enzyme, such as the decision tree model of 
Zhang et al. [15]. Particular enzymes may have broad or narrow substrate specificity and more than one 
enzyme may catalyse the same metabolic process. Software is available to predict binding to enzymes (e.g. 
docking interactions / binding affinities), sites of metabolism, metabolic stability of parent chemicals and 
potential metabolic routes. Software for identifying potential interactions between chemicals of interest 
and putative enzyme(s) are given in Table 3.  
1.2 Expression of enzymes in skin (and comparison to liver)  
If the enzyme(s) relevant to the metabolic route identified above is known to be present in the skin then 
metabolism via that route is a realistic possibility following dermal exposure. True confirmation of the 
presence of a given enzyme requires experimental verification using skin-based experimental systems. 
Much of our understanding of the metabolic capability of skin has been based on ex vivo experiments using 
rodent and porcine skin. However, recent ethical and legislative changes have driven researchers to explore 
non-animal and more human-relevant in vitro models. Excised human skin usually obtained from 
abdominal or breast reduction surgery is an attractive ex vivo tool that offers a native tissue structure and 
mixed cell populations but has limitations as an experimental model due to availability, individual variability 
and the limited time for which the tissue can be used after excision. To overcome these limitations, the last 
decade has seen a dramatic increase in the use of tissue engineered, reconstructed skin equivalents, with 
researchers looking for control over tissue supply and experimental reproducibility. First developed in the 
early 1980s three-dimensional skin equivalents are produced by culturing primary dermal keratinocytes on 
top of a dermal fibroblast-containing matrix at an air-to-liquid interface [16, 17]. Morphologically, the 
models display a stratified squamous epithelium that is highly keratinised and so closely mimics the native 
structure and organisation of human skin. These skin equivalents offer an advantage over ex vivo tissue as 
they can be cultured on demand and for longer periods of time, allowing detailed studies on the molecular 
mechanisms of skin homeostatic and disease processes as well as xenobiotic metabolism.  Their viability 
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over prolonged periods in culture enables enzyme kinetic assays to be performed either with freshly 
isolated tissue extracts or whole tissue. Skin equivalent models have been validated against native human 
tissue in terms of gene (microarray, qPCR) and protein (proteomic and immunoblot) expression. 
Furthermore, skin equivalent models are amenable to immunohistological examination to provide evidence 
of the specific expression of metabolising enzymes within the epidermis or dermis, as well as spectral 
analysis (Raman spectroscopy or mass spectrometry) to identify the distribution of metabolites within the 
tissue (see section 1.7). Such improvements in analytical methodology have led to more accurate 
identification and quantification of enzymes in skin. Van Eijl et al. reported a range of enzymes detected in 
human skin and skin models using proteomic analysis [18]. Enzymes detected in liver, but not in skin, and 
skin:liver expression ratios were also reported, enabling comparisons between the two organ systems: 36 
enzymes were detected in both skin and liver; 46 enzymes, including 13 cytochrome P450 proteins were 
detected only in liver. Protein levels of enzymes involved in conjugation, hydrolysis, dehydrogenation, 
carbonyl reduction, oxidoreduction and oxidation were detected in skin at levels 4-10 fold lower than in 
liver, but levels of cytochrome P450 were reported as being 300-fold lower. This confirms the earlier 
suggestion that phase II metabolism predominates in skin with phase I reactions having a lesser role, 
although experimental processes (such as freezing and thawing) may affect quantification. Certain enzymes, 
such as alcohol dehydrogenase 1, epoxide hydrolases 1 and 2, hydroxyacyl-coenzyme A dehydrogenase and 
aldo-keto reductase 1C1 and 1C2 are expressed at higher levels in skin than in liver [19]. The review of 
available in silico and in vitro methods for assessing dermal bioavailability by Dumont et al. provides an 
excellent overview of the state-of-the-art in skin metabolism research, collated from an extensive range of 
literature studies [19]. The paper provides tables for enzyme detection in skin using protein expression and 
mRNA studies and provides skin:liver expression ratios where available. Further details such as 
experimental procedures, subsections of skin analysed, use of fresh or frozen samples (all of which may 
influence the outcome of the investigations) are available within the references provided. Discrepancies in 
results concerning presence or absence of specific enzymes may result from differences in analytical 
methods such as: anatomical differences in skin section used; freezing of samples (affecting integrity of the 
enzyme system), limits of detection etc. Variability inherent in such test systems was highlighted by 
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Manevski et al. [20]. These authors reported a proof-of-principle study using human skin explants to 
investigate the metabolism of 11 substrates via phase II reactions. The study confirmed formation of 
metabolites following glucuronidation, sulfation, N-acetylation, catechol methylation, or glutathione 
conjugation processes; inter-individual variability was reported at a level of 1.4 – 13 fold in the analysis. 
Activity of a given enzyme in skin can only be confirmed by experimental methods. Once the presence of a 
given enzyme has been confirmed, there are a number of software packages that can predict whether or 
not a given chemical is a likely substrate for that enzyme (as discussed in section 1.1 above). Developments 
in this area are heavily reliant on continued experimental verification of enzyme activity and improvement 
in in silico methods to predict enzyme:substrate interactions. 
 
1.3 Reaction kinetics: predicting Vmax / Km / Kcat / CLint 
The rate at which metabolites are formed is another important factor in determining the time course of 
parent and metabolites in the skin and their potential to elicit toxicity. Rate of metabolite formation may be 
limited by the rate at which the parent molecule is presented to the metabolising enzymes (i.e. perfusion 
rate-limited for drugs that are readily metabolised) or may be limited by the capacity of the enzymes for 
poorly metabolised chemicals (i.e. low intrinsic clearance (Clint)). For many chemicals, particularly drugs, 
intrinsic clearance of the compound by liver enzymes has been measured. Using these data quantitative 
structure-activity relationship (QSAR) models have been developed for the prediction of intrinsic clearance, 
as measured in hepatocytes or microsomes [21, 22, 23, 24] and for total clearance of drugs [25, 26]. The 
publication of Pirovano et al. reports QSARs developed for intrinsic clearance covering both drugs and 
environmental pollutants [27].  
Clearance values can be used as an indication of the overall stability of the parent or conversely as the 
efficiency of metabolism by a specific enzyme. Adjustments are required when considering potential 
metabolism in skin versus liver as differences in enzyme expression and activity levels, as well as 
differences in perfusion between skin and liver, need to be taken into account. Inherent metabolic 
capability can be characterised in terms of Vmax (the maximum rate at which an enzyme catalyses a 
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reaction), Km (the substrate concentration at which half maximum rate of reaction is reached (i.e. 
indicating the affinity between enzyme and substrate) and Kcat (the number of substrate molecules each 
enzyme site converts to product per unit time, for a given enzyme concentration, when the enzyme is 
working at maximum efficiency). Measurements for Vmax and Km are intrinsically highly variable which 
complicates model development, however, it may be possible to develop local QSAR models for narrowly 
defined categories of chemicals. Resources such as the enzyme information system “Brenda” 
(http://www.brenda-enzymes.org/; accessed May 2017) provide an extensive database of Vmax, Km, Kcat 
and other values relating to enzyme kinetics from which further models may be developed, although it 
should be noted that there is very high variability in Km and Vmax values recorded, hence careful curation 
is required prior to selecting values for modelling. For certain enzymes there is a plethora of data but for 
other enzymes data are sparse. There are examples within the literature where QSAR models have been 
developed to predict relevant kinetic parameters using such data collations. For example, Pirovano et al. 
[28]  provide models for prediction of Vmax and Km for compounds metabolised by four enzyme classes 
(alcohol dehydrogenase (ADH), aldehyde dehydrogenase (ALDH), flavin-containing monooxygenase (FMO), 
and cytochrome P450, using data obtained from Brenda, from the review of QSARs for P450 enzymes 
published by Hansch et al. [29] as well as other resources. Hybrid quantum mechanics / molecular 
mechanics (QM/MM) methods are now being applied to understanding the specific mechanisms involved 
in catalysis by enzymes such as cytochrome P450. Such advances in mechanistic understanding of enzyme-
substrate interactions will provide further insight and more accurate computational models for predicting 
xenobiotic metabolism [30]. 
As data variability is high, one possibility is to predict a plausible range for the kinetic values rather finite 
values. Such an approach is analogous to that of Poulin and Krishnan who derived “theoretically plausible 
envelopes” of concentration in blood based on setting intrinsic clearance at theoretically possible minimum 
and maximum values [31]. This enables estimations to be made within a defined level of uncertainty. 
Software that may be used to predict Vmax, Km and intrinsic clearance are given in Table 3, although data 
on which such models are built are generally based on data from liver assays. In vitro verification of 
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predicted enzyme kinetics is invaluable for further model development and extension of the chemical space 
to which such models could be applied. 
 
1.4 Stability / reactivity of metabolite 
Once formed a metabolite itself may elicit desirable or toxicological effects, locally or remotely (following 
entry into the circulatory system) prior to further metabolism and/or its ultimate excretion from the body 
via renal, hepatic or other routes of elimination. Whilst metabolic activation is useful for administering pro-
drugs, adverse effects of reactive metabolites are of significant concern in toxicology. Reactive metabolites 
may interact with a range of biological macromolecules (such as proteins or DNA), resulting in an array of 
effects including skin or respiratory sensitisation, mitochondrial toxicity or damage to DNA.  The extent of 
damage elicited by a metabolite is a function of both the nature and the longevity of the metabolite i.e. 
whether the metabolite persists for sufficient time to cause a toxicological response or whether 
biochemical defences, or rapid clearance of the metabolite, obviate the response. Within drug discovery, 
drug candidates are routinely screened for potential reactive metabolite formation, using known structural 
alerts. Alerts for compounds with the potential to form reactive metabolites, in the context of drug 
discovery, have been reviewed by Stepan et al. [32]. Such alerts can be used to identify compounds 
associated with potential reactive metabolite formation following dermal exposure.  
 
1.5 The likelihood of a given reaction occurring 
Many potential reaction pathways to the formation of metabolites may be predicted from knowledge of 
organic reaction chemistry. However, the likelihood of any individual reaction occurring and leading to a 
given metabolite can be considered as a statistical question i.e. how often is the reaction actually observed 
in comparison to the number of instances it could be predicted to occur? Two sources of information are 
useful in predicting the overall likelihood of a reaction occurring. Firstly the overall extent of metabolism 
may be known as its converse (the fraction excreted unchanged in urine following oral administration) is 
often measured, particularly for drugs. Manga et al. developed a model to predict whether a drug would be 
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poorly or extensively metabolised following oral administration based on simple physico-chemical 
properties [33]. Secondly - assuming the chemical is subject to metabolism - then the more likely pathways 
can be predicted by statistical analysis of experimental databases of reactions. There are several empirical 
methods for ranking the most likely pathway for metabolism. PASS-BioTransfo gives the likelihood of a 
particular class of reactions occurring [34]; SPORCalc [35] and MetaPrint 2D (http://www-
metaprint2d.ch.cam.ac.uk/; accessed May 2017) ranks the most likely sites for metabolism in a molecule; 
TIMES (http://oasis-lmc.org/products/software/times.aspx; accessed May 2017) and Metadrug  
(https://lsresearch.thomsonreuters.com/pages/solutions/18/metadrug; accessed May 2017) give a 
probability for formation of a given metabolite; SyGMa (Systematic Generation of potential Metabolites) 
ranks predicted metabolites according to an empirically derived probability score[36]. Meteor Nexus 
(metabolite predictor software from Lhasa Ltd; https://www.lhasalimited.org/products/meteor-nexus.htm; 
accessed May 2017) uses a static scoring methodology to order predict metabolites according to a pre-
computed score of how predictive a particular biotransformation is, based on experimental data. A site of 
metabolism scoring function is also derived based on the static score but adapted appropriately using 
known data from similar compounds. Marchant et al. demonstrated that over-prediction of metabolites in 
Meteor Nexus could be reduced by incorporating a measure of the structural similarity of the query 
chemical to substrates with known experimental data [37]. As numerous metabolites are theoretically 
possible for any given chemical, it is important to rationalise those that are truly likely to be formed if a 
realistic safety assessment is to be performed. TIMES (TIssue MEtabolism Simulator ) generates a metabolic 
tree where propagation of metabolites is constrained to those more likely to be formed using a defined 
mathematical formalism as described by Dimitrov et al. 2011 and Mekenyan et al 2012. [38, 39]. 
As with other information for metabolism the majority of data are derived from liver studies. Translating 
this to the probability of the reaction occurring in skin requires several other factors to be taken into 
consideration, for example are the same enzymes present in liver and skin or are there alternative enzymes 
that may also catalyse the same biotransformation? The ratios of different enzymes have been shown to be 
significantly different in skin and liver, hence consideration needs to be given as to how that would 
influence the metabolism of a specific chemical. Deciding on the most probable metabolites in skin, needs 
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to be informed by the aforementioned experimental studies to determine the actual levels of enzyme 
expression and activity in skin. Whilst predictions of the most likely metabolites are useful, in vitro or in vivo 
experimental verification as confirmation or disproval of metabolite formation would aid refinement of 
such statistical algorithms (refer to section 1.7 below). 
 
1.6 Potential for induction / inhibition 
Induction or inhibition of liver enzymes has been recognised as a significant factor in altering the amounts 
of parent or metabolite(s) present within the body, occasionally with serious or unpredicted consequences. 
For example the increase in unplanned pregnancies in women using hormonal contraceptives and co-
medicating with St John’s wort has been attributed to the induction of cytochrome P450 enzymes by St 
John’s wort and the consequent increase in metabolism (hence reduction in circulating levels) of the 
hormonal contraceptive. Conversely, furanocoumarins in grapefruit juice have been shown to inhibit 
cytochrome P450s responsible for the metabolism of a wide variety of therapeutic agents (including anti-
arrhythmic agents, anti-histamines, statins etc) leading to highly elevated levels of these drugs and 
resultant, significant toxicity. Hence determining the potential for induction or inhibition of enzymes is 
extremely important for the pharmaceutical industry and has led to a significant amount of research into 
possible induction or inhibition of enzymes by drugs, food and herbal products. For dermal exposure (e.g 
application of personal care products) a chemical may be applied every day over many years, for leave-on 
products in particular this leads to long term exposure with potential for induction of enzymes. Although 
cytochrome P450 enzymes have been shown to have low basal levels of activity in the skin these have been 
shown to be highly inducible, with potential consequences for repeated exposure [40, 41]. Information on 
substrates, inducers and inhibitors are available in the literature, some of which has been compiled into 
useful on-line resources for example: 
https://static.medicine.iupui.edu/divisions/clinpharm/content/p450_Table_Oct_11_2009.pdf (accessed 
May 2017) provides a list of substrates, inhibitors and inducers of specific CYP1A2, 2B6, 2C8, 2C9, 2C19, 
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2D6, 2E1, 3A4, 3A5, and 3A7. Software for predicting the potential of a compound to act as an inhibitor of 
specific enzymes is given in Table 3. 
 
 1.7 The identity of the metabolites formed 
Identifying the structure of metabolites that may be formed from a given parent structure has been a 
subject of intense research over many years, particularly following oral exposure. There are many 
literature-based sources providing details of metabolites of specific compounds [14] and on-line resources 
such as Drugbank (www.drugbank.ca; accessed May 2017) which lists key metabolites for drugs. The 
Drugbank database contains records for over 8,000 drugs including marketed pharmaceuticals, 
experimental compounds and drugs withdrawn from the market. The information having been collated for 
pharmaceuticals has a clear emphasis on the oral route and liver metabolism. In recent years, however, 
there have been an increasing number of publications relating to identification of metabolites in skin. 
Unlike data following oral exposure there is no single comprehensive, collation detailing all metabolites in 
skin, therefore data of this nature is highly variable and incomplete. Data are available within literature 
reports for either individual compounds or for a small number of compounds; these data often require 
extraction from text, rather than being in tabular format. The current literature provides a limited amount 
of skin-specific metabolism data and in some cases a comparison between skin and liver metabolism, 
although the data are not readily accessible. Table 4 (and references therein) provides examples of the 
types of data available for chemicals (drugs and non-drugs) and their metabolites that have been found in 
skin. The table also indicates where differences have been detected between liver and skin metabolism i.e. 
different enzymes involved and differences in metabolites, where these are known. Note that the table 
provides representative examples of the types of information available and is not intended to be an 
exhaustive list of available skin metabolism data.  
Table 4 HERE   
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There are several software platforms available that enable users to predict potential metabolites, such as 
those listed in Table 3. Most data (and hence predictions) are focussed on liver, however, knowledge of 
relevant enzyme expression in skin enables appropriate adjustments to be made when comparing liver and 
skin metabolism. Note that many of the predictive software developed, being based on liver, has a 
significant focus on cytochrome P450 activity, within skin however, phase II metabolism is more 
predominant than phase I. The Organisation for Economic Co-operation and Development (OECD) QSAR 
Toolbox (http://www.oecd.org/chemicalsafety/risk-assessment/oecd-qsar-toolbox.htm; accessed May 
2017) is useful as it possesses two metabolism simulators; one based on liver metabolism and the other 
based specifically on skin metabolism. This enables differential predictions to be made automatically for 
skin versus liver. The Toolbox simulates 203 transformations in skin compared to 345 in liver, based on 
existing knowledge. Meteor Nexus software (Lhasa Ltd) also possesses functionality that enables phase I 
and phase II metabolites to be generated individually.  
Recent development in in vitro skin models linked to improvements in analytical methodology allows for 
more rapid identification of metabolites formed in skin that will help to refine existing predictive models. 
With the increased sensitivity and improved resolution of mass spectrometry analysers [48] the scope for 
detecting parent drugs and metabolites has greatly increased.  A multitude of analytic techniques have 
been used to detect compounds from homogenates made from excised skin or human skin models 
including liquid chromatography coupled to atmospheric pressure chemical ionisation mass spectrometry 
(APCI-LC-MS/MS) [49], ultra-performance liquid chromatography-quadrupole time-of-flight (TOF) mass 
spectrometry (MS) and gas chromatography (TOF–MS) [50]. The growing development of mass 
spectrometry imaging (MSI) techniques has further introduced an additional dimension that not only allows 
metabolite detection but further informs on the spatial temporal localisation of a compound within the skin 
layers [51]. MSI has allowed the detection of drugs and metabolites from freshly frozen tissue sections [52, 
53] and from formalin fixed tissue sections [54]. This information is being used to refine models for 
predicting skin metabolism, enabling comparison of predicted metabolites to those determined 
experimentally. 
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1.8 Development of skin metabolism simulators 
Table 1 and sections 1.1 – 1.7 have identified key elements associated with metabolism. It has been 
established that the majority of data available are derived from liver metabolism studies, hence prediction 
of skin metabolism requires appropriate adjustments to be made. However, it is also recognised that due to 
developments in tissue engineering and analytical methodology more in vitro data are becoming available 
that have been directly measured in skin or skin equivalents (e.g. identity and rate of formation of 
metabolites). This presents an opportunity to develop in silico simulators of skin metabolism directly rather 
than relying on information derived from liver studies. As more information becomes available this can be 
used iteratively to improve such skin metabolism simulators, for example by confining predicted 
metabolites in skin to those derived from the most likely metabolic routes, as identified by analytical 
observations. 
 
2. External exposure 
Whilst the above has focussed on predicting skin metabolism, clearly there are other key factors to 
consider in an overall risk assessment for dermal exposure of chemicals. Although significant, these 
ancillary factors are not the focus of the current paper, hence are only briefly introduced - the reader is 
referred to the corresponding references and software resources presented in Table 5 for further 
information.  
Table 5 HERE 
In the case of incidental dermal exposure, predicted environmental concentrations, workplace exposure 
limits or typical use-case situations may be used to determine realistic or worst case scenario estimations of 
exposure. Typically separate exposure models are derived for workers or consumers [56]. For intentional, 
dermal application, levels of exposure are more closely controlled. For drugs, the specified dosing regimen 
determines the amount applied, the area and frequency of application and whether or not the site is 
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occluded. Similarly, for personal care products, standardised exposure scenarios have been published that 
take account of the intended use of the product, site and frequency of application, wash-off or leave-on 
scenarios etc, [2]. A discussion of models relating to exposure is beyond the scope of the current paper, 
however, indicative models and sources of information are given in Table 5.  
 
3. Uptake and distribution within skin 
Other significant factors relate to the rate and extent of uptake (absorption) and distribution of the 
chemical through the various skin layers and skin cells. Dermal absorption data are available from the 
reports of the Scientific Committee on Consumer Safety (SCCS) for cosmetic ingredients and skin 
permeability data are available for 470 test substances from COSMOS DB version 2 
(https://cosmosdb.eu/cosmosdb.v2; accessed May 2017). Additionally, many models have been devised to 
predict dermal absorption or skin permeability. These models range from simple to complex including: 
simple discriminant functions (i.e. above particular cut-off values for molecular weight and/or lipophilicity, 
dermal absorption is less likely [57]; quantitative structure-property relationships that give a quantitative 
prediction of permeability based on correlation with physico-chemical descriptors [58, 59]; and more 
complex, complete kinetic models accounting for the rate and extent of diffusion into individual skin layers 
requiring more detailed input parameters [3, 6]. A full review of predictive models for skin uptake is beyond 
the scope of the work presented here, however, a detailed review of such models has been published by 
Mitragotri et al. [60]. Example software for the prediction of skin uptake is given in Table 5. 
In terms of uptake via skin there are many sources of variability, the influences of which are poorly defined; 
these include ethnicity, the hydration status of the skin, presence of skin microflora, factors relating to 
mixture effects and choice of formulation or vehicle. Models have been developed to predict the influence 
of some of these factors e.g. vehicle, mixture and formulation effects [7-9], however, much more work is 
required in this area. Predictive models with defined levels of uncertainty (e.g. providing estimations of 
maximum/minimum uptake) that reflect the level of variability in the in vivo system may offer a more 
realistic solution than attempts to predict finite values for uptake.  
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4. Potential to elicit toxicity  
The potential of a chemical to elicit a toxic effect in vivo is a consequence of both intrinsic hazard and the 
concentration-time profile of the chemical in the relevant organ or system. There is a vast amount of 
toxicity data currently available, much of which has been collated and curated into global repositories such 
as the OECD QSAR Toolbox (http://www.oecd.org/chemicalsafety/risk-
assessment/theoecdqsartoolbox.htm; accessed May 2017), DSSTox (https://www.epa.gov/chemical-
research/distributed-structure-searchable-toxicity-dsstox-database; accessed May 2017), AcTOR 
(https://actor.epa.gov/actor/home.xhtml; accessed May 2017), and eCHEMPortal 
(http://www.echemportal.org/echemportal/index?pageID=0&request_locale=en; accessed May 2017). 
Access to data for over 700, 000 chemicals is available via the interactive Chemical Safety for Sustainability 
(iCSS) CompTox dashboard (https://comptox.epa.gov/dashboard/; accessed May 2017) developed by the 
United States Environment Protection Agency (US EPA). This resource includes millions of predicted 
physico-chemical properties associated with the chemicals in the database. Where data are lacking, 
prediction of toxicity using both in vitro and in silico methods are well-established scientific tools. There are 
many software platforms available to predict a wide range of toxicities (or to identify structural features 
associated with toxicity i.e. structural alerts) as given in Table 5; prediction of skin sensitisation being of 
particular importance in terms of dermal exposure. Prediction of intrinsic hazard can be carried out for 
both the parent and metabolite(s); it is an inherent property determined by chemical structure. Whilst 
toxicity is an inherent property, overall predictions for toxicity may need to be adjusted to take account of 
local toxicity and differences in metabolites that may be produced when comparing oral versus dermal 
exposure. Physiologically-based pharmacokinetic (PBPK) models play an increasing role in toxicity 
prediction as they can be used to predict the concentration-time profiles of a chemical at any specific site 
within the body and are designed to be readily adapted for different routes of exposure. 
A PBPK model is a mechanistic, multi-compartment mathematical model that describes the time-course 
dynamics and overall kinetics of a xenobiotic throughout the body. This is achieved by describing the 
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different physico-chemical properties of the xenobiotic and the specific physiology of the organism, such 
that the evolution of the ADME processes can be accurately simulated in silico. Xenobiotic properties 
include tissue affinity, membrane permeability, enzymatic stability etc., while the organism/system 
component includes such properties as organ mass/volume and blood flow [63]. The structure of PBPK 
models typically revolves around the anatomical structure of the organism with different organs and tissues 
of varying perfusion rates being separated into distinct compartments. In the simplest case, these tissue 
compartments are treated as being well mixed, which is based on the idea that there is a rapid 
equilibration of the xenobiotic once it enters the tissue [61].  
Clearly, however, local tissue architecture could create spatially heterogeneous xenobiotic profiles within 
the tissue and, to enable capture of such spatial profiles, these local tissue features therefore should be 
incorporated into the PBPK framework. Mathematical modelling of these features in relation to 
transdermal drug transport has been a major area of research [62]. Seminal work by Higuchi (1960) [63], 
based on Fick’s law for transport processes, laid the foundation of current theories of skin penetration. 
Since then, a large number of modelling papers have been written attempting to describe various aspects 
of transdermal permeation (for reviews see [64] and [65]). These models range in complexity but are 
typically based on simple assumptions, such as a single layer of skin or a two layer composite. The norm is 
to treat each skin layer as a homogeneous medium with no distinct intra- and extra-cellular compartments 
[67, 68] and xenobiotic modification via metabolising enzymes has received little attention to date. 
Exceptions are the ‘bricks and mortar’ mechanistic models (e.g., [65] and [67]) which do account for 
multiple pathways (intercellular and transcellular) and metabolism has been included in several models [68-
71]. These approaches provide useful qualitative information but still suffer from a number of over-
simplifications of the skin structure, cellular xenobiotic transport and enzyme effects and are therefore 
limited in their quantitative predictive potential. To be able to move this work forward to a more predictive 
framework and one which can accurately predict spatial xenobiotic and metabolite skin profiles, ingredients 
such as cellular geometries, paracellular transport, transport of the xenobiotic across the cellular 
membrane as well as accurate enzyme kinetic information need to be properly measured and incorporated. 
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Training and validation of such a framework against spatial enzyme kinetic and metabolite data obtained 
from in vitro data will drive the generation of a software platform that will then have the ability to predict 
metabolite production and their rates of elimination for xenobiotic compounds in skin, which, when 
coupled to PBPK frameworks, will also then allow the exploration of systemic penetration and subsequent 
systemic effects. This is, of course, a significant task, but current advances in the in vitro and in silico work, 
such as that described above, is making great steps towards making such model development possible. 
Resources, such as the oCHEM database (https://ochem.eu/home/show.do; accessed May 2017) provide a 
range of experimental data serving as useful inputs for such PBPK models; note that data sharing in oCHEM 
is based on the wiki principle. 
The combination of information concerning external exposure, internal exposure (concentration-time 
profiles) and intrinsic toxicity, as outlined above, is essential in order for risk assessment to be performed. 
This enables identification of substances of concern or of no concern in terms of human health. Such 
information can be used to prioritise chemicals for further testing, inform decisions on control measures to 
be introduced or identify where alternatives need to be sought. 
 
Using the information in risk assessment 
Grouping and read-across approaches are now well-recognised as methods to aid the prediction of toxicity. 
Recent publications have provided guidance on the use of Integrated Testing Strategies (ITS) or Integrated 
Approaches to Testing and Assessment (IATA) and the importance of incorporating metabolic information 
into such predictions. As the use of grouping and read-across has become more prevalent, justification of 
analogue selection is essential to ensuring confidence in the prediction. Wu et al. provide a framework for 
evaluating the suitability of analogues for read-across which explicitly assess factors relating to the 
potential metabolism of the analogue and target [72]. These factors include: the strength of evidence 
supporting the occurrence of the reaction (e.g. in vivo human/animal data); influence of the route of 
exposure and relevance of metabolism to the endpoint. Recently there have been several publications 
promoting the use of read-across and establishing a framework to support broader acceptance of the 
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methods. For example Patlewicz et al. present factors to be considered to improve consistency and 
acceptability of read across predictions [73]. Within the framework, specific reference is made to potential 
metabolism i.e. are differences expected between metabolic pathways (and/or rate) for the target and the 
analogue bearing in mind the route of exposure. Tollefsen et al. discuss Adverse Outcome Pathways (AOPs) 
and how they can support IATA again identifying where metabolic information can be incorporated when 
performing risk assessment [74]. These recent publications provide a useful framework for how information 
relating to different aspects of metabolism (likelihood of reaction occurrence, route of exposure etc) can be 
usefully integrated into toxicity assessment. 
 
Conclusions  
The skin is an important route for both incidental and intentional exposure to a wide range of chemicals 
including pollutants, drugs and personal care products. In terms of risk assessment, to ascertain whether a 
chemical is likely to be of concern or no concern following dermal exposure requires many factors to be 
considered in concert, particularly the influence of skin metabolism. Traditionally, metabolism studies have 
focussed on the liver as the main organ of metabolism, hence there are more data available concerning 
liver metabolism and the oral route of exposure. Research into skin metabolism has been a more recent 
endeavour driven, in part, by the advances in analytical methodology which enables detection and 
quantification of ever lower concentrations of enzymes and metabolites. There is an increasing body of 
evidence concerning which enzymes are expressed in skin and how enzyme activity varies between liver 
and skin. Additionally, existing data, based on liver metabolism studies, can be leveraged and applied to the 
question of skin metabolism, providing appropriate adjustments are made for differences in uptake, 
distribution and enzyme expression / activity levels. The re-purposing of data derived from liver, using 
appropriate adjustments and the battery of in silico tools that are available enables the prediction of many 
key factors relating to skin metabolism. Further data, currently being generated from in vitro skin / skin 
models will be invaluable in aiding in silico model development and refinement as well as verification of 
model suitability and the coverage of the models in terms of chemical space. Combining all of this 
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knowledge will enable more robust models to be developed and will engender greater confidence in risk 
assessments of chemicals following dermal exposure. 
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Table  1. Summary of the information requirements for predicting skin metabolism and potential sources for leveraging data from existing studies  
Information Required Potential Sources of Information* Applicability to dermal route or adjustments  
required 
Enzyme(s) responsible 
- consider affinity, selectivity and competing 
pathways 
Existing data on biotransformations of parent or “similar” compounds 
available in literature or on-line databases. 
Software available to identify whether compounds are potential 
substrates for individual enzymes and to predict enzyme-substrate 
interactions (e.g. binding affinity / docking calculations). 
Existing data largely derived from liver studies; 
differences in enzymes present in skin versus liver 
need to be accounted for. 
Regional enzyme expression level Increasing availability of qualitative and quantitative experimental data 
for regional enzyme expression and activity levels (e.g. detection in 
native skin or skin models, mRNA and protein analysis; liver:skin 
expression ratios). 
- NB high variability in measurements between individuals and 
between anatomical sites of the same individual; significant inter-
species differences. 
Many data generated for liver historically, 
however, recently, more focus on dermally 
expressed enzymes; comparison of expression 
ratios enables adjustments to be made comparing 
liver:skin activity. 
Rate of reaction 
- Vmax; Km; Kcat 
 
Data available in literature and on-line compilations (e.g 
http://www.brenda-enzymes.info/; accessed May 2017); limited 
number of QSAR models currently available (curation of existing data 
may enable more models to be developed); software packages 
available to predict Vmax and Km. 
Relate to intrinsic properties of a given enzyme 
and substrate; differences in rate at which parent 
is presented to metabolisng enzymes via the 
different routes needs to be considered. 
Likelihood of reaction  
- Overall potential to be metabolised 
 
 
- Reaction occurence ratio 
Literature data available for overall likelihood of metabolism (i.e. 
fraction excreted unchanged / total clearance (mostly for drugs); QSAR 
models available for clearance and fraction excreted unchanged. 
 
Occurrence ratios can be statistically derived from known reactions 
and applied within predicitive software to rank more likely metabolic 
routes. 
Most data and models generated using liver 
studies; differences between skin and liver need 
to be accounted for (e.g. the likelihood of a given 
metabolic route given differences in expression 
ratios between the two organs). 
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Potential induction / inhibition Known for some enzymes (e.g. potential for induction / inhibition of 
enzymes following co-administration of drugs well documented); 
computer packages available that predict potential for enzyme 
inhibition. 
Current data mostly dervied from liver studies; 
consider differences in exposure scenarios – e.g. 
application of personal care products may be at 
low dose over many years with potential to induce 
enzyme activity. 
Identity of metabolite(s) Considerable amount of data available from literature and on-line 
resources providing known metabolites of many chemicals 
(predominantly drugs). 
Wide range of software packages available to predict potential 
metabolites from a given chemical structure. 
Majority of packages developed using data from 
liver studies; consider applicability to skin where 
expression of the relevant enzyme is reduced or 
absent.  
Note: OECD QSAR Toolbox has a specific skin 
metabolism simulator; Meteor Nexus (Lhasa 
Limited, Leeds) enables metabolites derived from 
phase I or phase II  enzymes to be generated 
separately. 
Stability of metabolite 
- potential for further metabolism 
- potential to form reactive metabolites 
Complete metabolic trees may be predicted for compounds including 
phase I and phase II metabolism. 
Structural alerts developed to identify potential reactive metabolites. 
Software to predict metabolic trees largely 
developed using data from liver – requires  
consideration of differential enzyme expression 
between skin and liver. 
Structural alerts are based on intrinsic structural 
features, however, potential toxicity is also 
dependent on site of metabolite formation (e.g. 
liver toxicity versus skin sensitisation). 
*Details of software are given in Table 3; literature resources, databases and existing (Q)SARs are detailed in Section 1
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Table 2. Summary of the additional information requirements relevant to risk assessment and potential sources of data 
Information Required Potential Sources of Information* Applicability to dermal route or adjustments 
required 
External Exposure Scenarios 
Extent of incidental exposure: 
Overall exposure in the workplace, home or 
public areas relating to amount, duration, 
frequency of exposure and control measures. 
Several methods are available to measure or model dermal exposure at 
work, in the home or in public areas. A wide range of methodologies and 
tools (including DREAM, DERM, EASE, MEASE, Riskof Derm, ECOTOC 
TRA, BEAT, ConsExpo, Spray Expo and a range of pesticide-specific 
models) were reviewed in detail by an expert working group of the 
World Health Organisation [1]. 
 Derived for dermal exposure 
Extent of intentional exposure: 
Exposure as a result of intentional  
application of pharmaceuticals or personal 
care products, relating to amount, duration, 
frequency of exposure, wash-off/leave-on 
scenarios and/or use of occlusion. 
Data for application of pharmaceuticals are available from the relevant 
prescribing information / dosing regimen.  
The Notes of Guidance from the Scientific Committee on Consumer 
Safety [2] provide details for estimating systemic exposure following 
dermal application of personal care products based on in-use scenarios.  
Includes tables for estimating areas of exposure and frequency of 
application based on use cases (e.g. hand wash, body lotion, hair dyes 
etc).  
 Derived for dermal exposure 
Distrbution Within Skin 
Dermal absorption 
Skin permeability 
Exisiting collations within the literature; reports of the Scientific 
Committee in Consumer Safety (SCCS); databases (e.g. COSMOS db, 
http://www.cosmostox.eu; accessed May 2017); (Quantitative) 
Structure-Activity Relationship ((Q)SAR) models; computer packages. 
Derived for dermal exposure 
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Rate and extent of uptake in skin layers Spreadsheet-based compuational algorithms using simple physico-
chemical properties that may be measured or predicted using freely 
available software [3, 4]; mathematical models for drug transport in skin 
[5-6]. 
Physiologically-based pharmacokinetic (PBPK) models; computer 
packages. 
Derived for dermal exposure or, in the case of 
PBPK modelling, readily adapted to dermal 
route. 
Effect of formulation, solvent, vehicle, 
mixture components, occlusion, etc 
Limited number of QSAR models available relating to how the effect of 
formulation, choice of solvent or vehicle may affect dermal uptake [7-9]. 
Derived for dermal exposure 
Potential to Elicit Toxicity 
Prediction of intrinisc hazard 
(for both parent and metabolite) 
Wide range of software available to predict toxicity or to identify 
presence of strucutral features associated with toxicity (structural 
alerts). 
Inherent property of parent or metabolite, 
determined by its structure; intrinsic hazard is 
not dependent on route of administration, 
although resulting toxicity may be dependent on 
route of administration. 
Distribution with organism; subsequent 
location of parent or metabolite 
PBPK models can be used to predict the time-course of parents and 
metabolites in individual organs of the body. 
PBPK models are designed to be flexible 
concerning route of administration, therefore 
are readily adjustable for dermal exposure. 
*Details of computer packages given in Table 5; literature resources, databases and existing (Q)SARs are detailed in Section 1 
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Table 3. In silico tools (predominantly based on liver metabolism) to assist in the prediction of skin metabolism 
Software Capability / Methodology  Availability Key Reference or Website 
Tools to identify biotransformation pathways, sites of metabolism and the enzyme(s) responsible 
ACD/Percepta Platform 
(Regioselectivity of 
metabolism module) 
Uses probabilistic models to predict likely sites of metabolism for the 
main metabolic reactions mediated by human liver microsomes and 
five key individual CYPs (CYP3A4, CYP2D6, CYP2C9, CYP2C19 and 
CYP1A2). Provides a reliability score for predictions based on 
similarity to training set.  
Commercial http://www.acdlabs.com/products/pe
rcepta/predictors.php; accessed May 
2017 
ADMET Predictor 
(metabolism module) from 
Simulations Plus 
Identifies likely sites of metabolic oxidation by CYP P450 enzymes: 
1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 3A4. 
Classifies whether a molecule is likely to be a substrate for these CYP 
isoforms. 
Uses a curated and updated version of the Accelrys Metabolite 
database, including additional literature datasets, to train models.  
Commercial http://www.simulations-
plus.com/Default.aspx; accessed May 
2017 
ChemTunes BioPath - 
Metabolism Database 
Provides liver metabolism information for nearly 500 xenobiotics 
(drugs) over 2000 enzymatic reactions. Also houses over 4,000 
enzymatic reactions for nearly 3,000 molecules involved in 
endogenous metabolism. Searchable for reaction centres, types and 
pathways.  
Commercial; Free evaluation 
possible upon request  
https://www.mn-
am.com/php/profile.php; accessed 
May 2017 
CypScore Predicts likely sites of metabolism for CYP 450-mediated 
metabolism; uses six models for key oxidation reactions. Models 
based on reactivity descriptors from surface-based properties (using 
Parasurf based on AM1 semi-empirical molecular orbital theory); 
trained using Bayer Schering in-house MajorMetabolite database. 
CypScore Pipeline Pilot 
Components freely available 
(differential licensing 
/support for academia, 
government, industry) 
http://www.cacheresearch.com/cepos
.html; accessed May 2017 
FAst MEtaboliser (FAME) Predicts sites of metabolism – Phase I and ll metabolism can be 
predicted, both global and species-specific (human, rat and dog) 
models are available; uses random forest methodology, based on 
seven chemical descriptors; trained on over 20,000 diverse 
molecules. 
Freely available from authors 
for academia and non-profit 
organisations 
[11] 
IMPACTS 
 
Predicts sites of metabolism for CYP mediated reactions using 
docking, transition state modelling and substrate reactivity 
prediction. 
Commercial http://www.molecularforecaster.com/
products.html; accessed May 2017 
  
MetaPred web server Predicts CYP isoform responsible for metabolising drug molecules 
using a Support Vector Machine approach (considers substrates of 
Freely available http://crdd.osdd.net/raghava/metapr
ed/; accessed May 2017 
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CYP3A4, CYP2D6, CYP1A2, CYP2C9 and CYP2C19). 
MetaPrint2D Predicts sites of metabolism in human, rat and or dog based on 
knowledge derived from data mining and statistical analysis. 
Freely available http://www-
metaprint2d.ch.cam.ac.uk/metaprint2
d; accessed May 2017 
MetaSite Predicts metabolic transformations for CYP and flavin-containing 
monooxygenase mediated phase I reactions; takes account of 
enzyme substrate recognition and chemical transformations. 
Identifies likely sites of metabolism and potential metabolites 
(ranked based on site of metabolism). 
Commercial http://www.moldiscovery.com/softwa
re/metasite/; accessed May 2017 
MEXAlert A screening tool to predict sites on a molecule where phase II 
metabolism (i.e. conjugation reactions) may occur indicating high 
probability of first pass elimination from the body. 
Commercial http://www.compudrug.com/mexaler
t; accessed May 2017 
SMARTCyp Predicts site of metabolism for CYP mediated reactions (CYP1A2, CYP 
CYP1A2, CYP 2A6, CYP2B6, CYP2C8, CYP2C19, CYP2E1, CYP3A4) by 
matching fragments with those in a fragment library for which 
reactivities have been pre-computed using density functional theory, 
transition state calculations and solvent accessible surface area. 
Freely available http://www.farma.ku.dk/smartcyp/in
dex.php; accessed May 2017 
StarDrop P450 
Metabolism Prediction 
module130  
Predicts sites of metabolism and relative vulnerability of that site for  
CYP3A4, CYP2D6, CYP2C9, CYP1A2, CYP2C19, CYP2C8 and CYP2E1 
mediated reactions, using quantum mechanical simulations of 
chemical reactions. 
Commercial http://www.optibrium.com/stardrop/
stardrop-p450-models.php; accessed 
May 2017 
VirtualToxLab Models binding of small molecules to CYP1A2, CYP2D6, CYP2C9 and 
CYP3A4. 
Freely available for 
universities, government 
agencies, regulatory bodies 
and non-profit organisations 
http://www.biograf.ch/index.php?id=
projects&subid=virtualtoxlab; 
accessed May 2017 
WhichCyp Predicts which CYP isoform may bind query drug-like molecules 
(considers CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4). 
Freely available http://130.225.252.198/whichcyp/ind
ex.php; accessed May 2017 
Tools to predict reaction kinetics (Vmax, Km, CLint) 
ADMET Predictor 
(metabolism module) from 
Simulations Plus 
Predicts Km and Vmax values for hydroxylation catalysed by CYP 
P450 enzymes: 1A2, 2C9, 2C19, 2D6, 3A4; predicts CLint values 
resulting from metabolic activity of these five enzymes. 
Uses artificial neural network ensembles and 2D molecular 
descriptors; trained using experimental literature data. 
Commercial http://www.simulations-
plus.com/Default.aspx; accessed May 
2017 
Tools to predict potential for enzyme inhibition 
Biovia Pipeline pilot Predicts CYP 2D6 enzyme inhibition. Commercial http://accelrys.com/products/datashe
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ADME-Tox  ets/qsar-admet-and-predictive-
toxicology-with-ds.pdf; accessed May 
2017 
oCHEM (online chemical 
database with modelling 
environment) 
Predicts potential of a compound to inhibit CYP3A4, CYP2D6, 
CYPC19, CYP2C9 and CYP1A2. 
Freely available https://ochem.eu/home/show.do 
Tools to predict the identity of the metabolites formed (likelihood of a particular reaction occurring or metabolite forming) 
ChemTunes/ToxGPS Liver 
BioPath workflow 
Generates metabolites based on the reaction rules learned from the 
ChemTunes BioPath Database using reaction chemotype rules  to 
identify reactive sites; gives prioritised metabolites 
Commercial https://www.mn-
am.com/products/toxgps; accessed 
May 2017 
META Ultra Uses a database of 15, 000 to predict sites of metabolism and 
metabolite trees for query chemicals human metabolite 
transformations. 
Commercial http://www.multicase.com/meta-
ultra; accessed May 2017 
Metabolexpert A rule-based system for predicting potential metabolites in humans, 
animals or plants; presents results as a metabolic tree. 
Commercial http://www.compudrug.com/metabol
expert; accessed May 2017 
MetaSite Predicts structures of the most likely metabolites of a compound, 
ranking is derived from the site of metabolism prediction (see 
above). 
Commercial http://www.moldiscovery.com/soft_
metasite.php; accessed May 2017 
Meteor Nexus Uses expert knowledge-based rules to predict metabolites; results 
are presented as an interactive tree with supporting data. Scoring 
can be applied to ascertain the relative likelihood of a metabolite 
being observed.  
Lhasa is a “not-for-profit” 
organisation 
https://www.lhasalimited.org/meteor
/; accessed May 2017 
MetaPrint 2D-react 
 
Highlights potential sites of metabolism and indicates relative 
likelihood of metabolism occurring at these sites; identifies potential 
reactions and depicts metabolites. Uses data mining of Metabolite 
database and probabilistic scoring. 
Freely available http://www-
metaprint2d.ch.cam.ac.uk/metaprint2
d-react; accessed May 2017 
OECD QSAR Application 
Toolbox 
Predicts metabolites following skin or liver metabolism of a 
compound of interest; contains a database of known 
biotransformations. 
Freely available https://www.qsartoolbox.org; 
accessed May 2017 
 
TIMES Predicts metabolic maps using a library of biotransformations and 
abiotic reactions; transformations can be prioritised based on 
probability of occurrence. 
Commercial http://oasis-
lmc.org/products/software/times.asp; 
accessed May 2017 
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Table 4. Representative examples of the types of data available relating to skin (versus liver) metabolism 
Parent compounds Information available relating to skin / liver metabolism Reference 
2-butoxyethanol; ethanol Rat skin demonstrated to metabolise 2-butoxyethanol and ethanol in presence of NAD+ suggesting aldehyde 
dehydrogenase (ALDH) and alcohol dehydrogenase (ADH) activity; relative expressions of isoforms of ADH 
between skin and liver influence capacity to metabolise alcohols of differing chain length. Rat skin 
predominantly expresses ADH4 whereas in liver cytosol ADH1 predominates. 
[42] 
Methylsalicylate; PABA  
(p-aminobenzoic acid); 
dapsone; 
sulfamethoxazole; 
minoxidil; betamethasone 
17-valerate; propranolol; 
capsaicin 
Provides evidence for expression of a range cytochromes P450, flavin monooxygenases, glutathione S-
transferases, N-acetyl transferases and sulfotransferases (at mRNA and / or protein level of expression) in 
skin. 
The following biotransformations are reported for skin: methylsalicylate metabolised to salicylate; PABA, 
dapsone and sulfamethoxazole metabolised to N-acetyl metabolites. Dapsone and sulfamethoxazole 
undergo N-hydroxylation - in skin flavin containing monooxygenase 3 (FMO3) and peroxidases are likely to 
be responsible for this transformation, although in liver this is accomplished by CYP2C9 (lacking in skin); 
minoxidil is metabolised to minoxidil sulphate; betamethasone 17-valerate metabolised to active 
betamethasone; oxidative metabolites of propranolol observed; capsaicin shown to undergo hydrolysis and 
oxidation. 
[10] 
4-amino-2-hydroxytoluene 
(AHT) 
N-acetyl AHT; AHT sulphate and AHT glucuronide detected; differential metabolism reported depending on 
route of administration (intravenous, oral or dermal). 
[43] 
PABA, benzocaine, azo 
colour reduction products; 
testosterone; estradiol 
Compounds containing primary amino group were substrates for N-acetyltransferase activity in skin; 
reference provides evidence for differential expression of a range of enzymes between skin and liver; 
metabolism detected by loss of parent in some cases where metabolites could not be identified; skin 
preferentially forms 5α-hydroxy metabolites of testosterone whereas liver forms both α and β isomers; also 
formed metabolites that co-chromatographed with 5x-androstane-3,17-diol; 4-androstane- 3,17-dione; and 
5α-dihydrotestosterone. 
[44] 
Benzoic acid, benzocaine, 
PABA; methylsalicylate; 
benzyl alcohol 
Approximately 7% of the absorbed dose of benzoic acid formed hippuric acid (glycine conjugate of benzoic 
acid); 80% of absorbed benzocaine underwent N-acetylation with <10% undergoing ester hydrolysis; PABA 
also metabolised to N-acetyl derivative; methylsalicylate hydrolysed by esterases to salicylic acid and 21% 
further metabolised via glycine conjugation to salicyluric acid; benzyl alcohol oxidised to benzoic acid; aryl 
hydrocarbon hydroxylase detected at >10:1 ratio between liver:skin. 
[44] 
Benzo[a]pyrene; 
trinitrobenzene; 
phenanthrene 
Benzo[a]pyrene hydrolysed to benzo[a]pyrene 7,8,9,10-tetrahydrobenzo[a]pyrene, nitro groups on 
trinitrobenzene reduced to amino groups which may be further acetylated to acetamide derivative – 1,3,5-
benzene triacetamide and 3,5-dinitroaniline detected; phenanthrene metabolised to 9,10-dihydrodiol, 3,4-
dihydrodiol, 1,2-dihydrodiol and traces of hydroxyl phenanthrenes. 
[45] 
Butylated hydroxytoluene 
(BHT) 
4-hydroxy derivative of BHT detected in skin. [46] 
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Trans cinnamic alcohol; 
trans-cinnamaldehyde; 
Formation of trans-cinnamic acid and cinnamic alcohol via alcohol dehydrogenase and aldehyde 
dehydrogenases. 
[47] 
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Table 5. In silico tools to assist in the prediction of additional factors relevant to risk assessment 
Software Capability / Methodology Availability Key Reference or Website 
Tools to predict dermal exposure 
ConsExpo Web A mathematical model used to assess exposure to chemicals from 
everyday consumer products (e.g. household cleaning products and 
personal care products (provided by the National Institute for Public 
Health and the Environment, Netherlands), considers inhalational, 
oral and dermal exposure. 
Freely available (after 
registration) 
http://www.rivm.nl/en/Topics/C/Cons
Expo; accessed May 2017 
ECETOC TRA  A tool for Targeted Risk Assessment (TRA) provided by the European 
Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC). 
Calculates risk of exposure from chemicals to workers, consumers 
and the environment. 
Freely available (after 
registration) 
http://www.ecetoc.org/tools/targeted
-risk-assessment-tra/; accessed May 
2017 
RISKOFDERM The outcome of a 5th Framework Programme of the European 
Community, providing a Toolkit for predicting dermal exposure. 
Freely available (after 
registration) 
http://www.eurofins.com/consumer-
product-testing/services/research-
development/projects-on-skin-
exposure-and-protection/riskofderm-
skin-exposure-and-risk-assessment/; 
accessed May 2017 
Stoffenmanager 
(substance manager) 
Web-based quantitative exposure modelling tool for both 
respiratory and dermal exposure. 
Freely available (after 
registration) 
https://stoffenmanager.nl/; accessed 
May 2017 
Tools to predict uptake in skin 
DermWin Predicts dermal permeability coefficient (Kp); part of the Estimation 
Programs Interface (EPI) Suite software, developed by the US 
Environment Protection Agency. 
Free http://www.epa.gov/tsca-screening-
tools/download-epi-suitetm-
estimation-program-interface; 
accessed May 2017 
Excel spreadsheet-based 
model 
A spreadsheet-based model to estimate bioavailability following 
dermal exposure, predicts transient skin absorption through stratum 
corneum, viable epidermis and dermis. 
Free [3] 
Skin-in-Silico Predicts absorption and permeation of chemicals and formulations 
into and through skin.  
Commercial https://www.xemet.com/en/products
/#skin; accessed 2017 
Tools to predict toxicity or to identify structural features associated with toxicity 
Biovia Discovery Studio Predicts a range of ADMET properties including hepatotoxicity and Commercial http://accelrys.com/products/collabor
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(incorporating TOxicity 
Prediction by Komputer 
Assisted Technology -
TOPKAT) 
identifies undesirable features using published SMARTS. 
TOPKAT predicts many toxicity endpoints (such as mutagenicity, 
carcinogenicity, developmental toxicity, LC50 (rat, fish, daphnia), skin 
and eye irritancy. 
ative-science/biovia-discovery-
studio/qsar-admet-and-predictive-
toxicology.html; accessed May 2017 
Case Ultra Models Provides a collection of toxicity model bundles for endpoints 
including hepatotoxicity, renal toxicity, developmental and 
reproductive toxicity, skin and eye toxicity etc. 
Commercial http://www.multicase.com/case-
ultra-models; accessed May 2017 
ChemTunes ToxGPS A knowledgebase for toxicity predictions to support safety 
evaluation and risk assessment of chemicals. Provides toxicity 
outcomes by using both QSAR and rule-based approaches. Statistical 
QSAR models are stratified across the mechanism of action pathways 
and the structure rules, developed by domain experts are enhanced 
by chemoinformatics approaches. Both QSAR and rule-based 
outcomes are then combined to reflect the weight of evidence of all 
information. The predictions are linked directly to large/high quality 
ChemTunes toxicity database through nearest neighbours. 
Commercial https://www.mn-am.com/products; 
accessed May 2017 
Chemotyper Identifies chemical chemotypes (substructures or subgraphs) within 
a dataset of chemicals that may be used to search for structural 
alerts for toxicity. 
Freely available https:chemotyper.org; accessed May 
2017 
DEREK Nexus Uses rules derived from expert knowledge to predict toxicity 
endpoints including carcinogenicity, mutagenicity, genotoxicty, skin 
sensitisation, teratogenicity, irritation respiratory sensitisation and 
reproductive toxicity; provides a reasoned prediction of the 
likelihood of the toxicity. 
Lhasa is a “not-for-profit” 
organisation 
https://www.lhasalimited.org/product
s/derek-nexus.htm; accessed May 
2017 
HazardExpert Pro Uses a rule-based system to predict oncogenicity, mutagenicity, 
teratogenicity, membrane irritation, sensitivity, immunotoxicity and 
neurotoxicity. 
Commercial http://www.compudrug.com/hazarde
xpertpro; accessed May 2017 
Leadscope QSAR Models Provides a series of QSAR models to predict endpoints including 
(non-human) developmental, genetic, reproductive and 
neurotoxicity and human cardiac, hepatobiliary and urinary tract 
toxicity. Also offers a rule-based system for genetic toxicity alerts 
based on publically-available alerts and a toxicity database of over 
180,000 chemical records. 
Commercial http://www.leadscope.com/model_ap
pliers/; accessed May 2017 
oCHEM (online chemical 
database with modelling 
environment) 
Possesses a range of predictive models (including AhR activation, 
AMES mutagenicity etc) and structural alerts that can be used to 
screen chemicals for molecular features associated with toxicity. 
Freely available https://ochem.eu/home/show.do; 
accessed May 2017 
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OECD QSAR Toolbox The Toolbox uses existing data to fill gaps in knowledge for a range 
of (eco)toxicity endpoints. It identifies relevant structural features 
for a “target” compound that may be associated with a particular 
mechanism of toxicity (for example structural alerts associated with 
skin sensitisation, mutagenicity, carcinogenicity etc). Other 
compounds within its databases possessing the same characteristics 
as the “target” are identified enabling a read-across prediction. The 
Toolbox includes biotic and abiotic metabolism simulators enabling 
information regarding metabolites to be incorporated in read-across 
predictions. 
Freely available http://www.oecd.org/chemicalsafety/
risk-
assessment/theoecdqsartoolbox.htm; 
accessed May 2017 
[55] 
(Prediction of Activity 
Spectra for Substances) 
PASS online 
Predicts over 3,500 types of biological activity (including 
pharmacology, toxicity and interaction with enzymes or 
transporters) using chemical structure alone. Prediction is based on 
analysis of structure activity relationships for >250,000 substances. 
Freely available (after 
registration) 
http://www.way2drug.com/passonlin
e/; accessed May 2017 
ToxPredict Estimates hazard from chemical structure, provides 16 models for 14 
toxicity endpoints. 
Freely available https://apps.ideaconsult.net/ToxPredi
ct; accessed May 2017 
Toxtree Estimates toxic hazard for a range of endpoints (human health and 
environmental) based on a decision tree approach; encodes 
structural alerts for skin sensitisation, activity in micronucleus assay, 
predicts skin and eye irritation, biodegradation etc. 
Freely available http://toxtree.sourceforge.net/; 
accessed May 2017 
VEGA  Virtual models for property Evaluation of chemicals within a Global 
Architecture (VEGA) provides a platform for in silico models to 
support safety evaluation of chemicals. VEGA is a combination of 
QSAR and read-across providing models for toxicity endpoints 
(including skin sensitisation, carcinogenicity, mutagenicity etc) and a 
tool enables evaluation of the result by consideration of the 
applicability domain of the model. 
Freely available http://www.vega-qsar.eu/; accessed 
May 2017 
VirtualToxLab Simulates and quantifies the interaction between a chemical of 
interest and biological target proteins known to trigger adverse 
effects (androgen, aryl hydrocarbon, estrogen α, estrogen β, 
glucocorticoid, hERG, liver X, mineralocorticoid, progesterone, 
thyroid α, thyroid β and peroxisome proliferator-activated 
receptors), uses docking combined with QSAR approaches. 
Freely available for 
universities, government 
agencies, regulatory bodies 
and non-profit organisations 
http://www.biograf.ch/index.php?id=
projects&subid=virtualtoxlab; 
accessed May 2017 
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Figure 1. Factors that govern the potential for a parent or metabolite to elicit toxicity and types of data required to aid prediction 
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Leveraging existing data from liver metabolism studies 
 
 
 
  
 
 
Environmental Pollutants  
●   Predicted environmental 
concentrations 
 
 
 
 
 
Occupational Exposure 
●   Anticipated workplace exposure 
levels / control measures 
Drug delivery 
●   Site, frequency, duration of 
administration; occlusion 
Personal Care Products 
●   Site, frequency, duration of 
application; wash-off / leave on 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
External Exposure Scenarios 
Incidental Exposure Intentional Exposure 
Biotransformation pathway 
●  Enzyme(s) responsible 
●  Selectivity, competition 
 
 
 
 
 
Likelihood of reaction 
●  Fraction unchanged   
●  Reaction occurrence ratio 
 
 
 
 
 
 
Uptake and distribution into and through skin layers, skin cells, vasculature and lymphatic system 
● Influence of formulation; vehicle; mixture effects; skin hydration; site of administration; ethnicity 
 
Rate of reaction 
●  Vmax, Km, Kcat 
 
 
 
 
Enzyme expression in skin 
●  Regional differentiation / 
comparison to liver 
 
 
 
Potential for enzyme 
induction / inhibition 
 
 
 
 
 
Identity of metabolite(s) 
 
 
 
 
 
Potential to Elicit Toxicity 
Uptake and Distribution Within Skin 
Skin Metabolism 
 Parent 
 
 
Figure
  
 
 
 
Prediction of intrinsic hazard 
 
Potential for distribution to site of local / systemic toxicity 
